Eosinophilic oesophagitis and type 2 inflammation multimorbidity: an opportunity for biologic treatment

Abstract

Eosinophilic oesophagitis is a chronic inflammatory disorder of the oesophagus, diagnosed by clinical symptoms of oesophageal dysfunction and histological evidence of eosinophilic infiltration of the oesophagus with a minimum threshold of 15 eosinophils per high-power field, in the absence of other systemic and local causes of oesophageal eosinophilia.1 Cumulative data suggest that eosinophilic oesophagitis is driven by a type 2 inflammatory response, associated with the release of key cytokines including IL-4, IL-5, and IL-13.